Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Brand Name :
Lupkynis
Synonyms :
voclosporin
Class :
Calcineurin Inhibitors
Dosage forms & Strengths:
Adult:
Capsule
7.9 mg
In case of mild hepatic impairment, reduce the dose to 15.8 mg twice daily:
23.7
mg
Capsule
Orally
twice a day
Safety and efficacy are not seen in pediatrics
Safety and efficacy are not seen in pediatrics
Refer to adult dosing
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
voclosporin: they may enhance the serum concentration of CYP3A4 Inhibitors
voclosporin: they may enhance the serum concentration of CYP3A4 Inhibitors
voclosporin: they may enhance the serum concentration of CYP3A4 Inhibitors
voclosporin: they may enhance the serum concentration of CYP3A4 Inhibitors
voclosporin: they may enhance the serum concentration of CYP3A4 Inhibitors
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk of serious infections
the effect of voclosporin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of voclosporin
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
It may enhance the metabolism when combined with dexamethasone
It may enhance QTc interval when combined with lithium
the peril or acuteness of adverse effects can be elevated when stepronin is combined with voclosporin
when voclosporin and melphalan combine the immunosuppressive effects of both the drugs are enhanced and lead to increased risk of infection
when both drugs are combined, there may be an increased risk of nephrotoxicity and ototoxicity
may raise the risk of nephrotoxicity
may raise the risk of nephrotoxicity
when both drugs are combined, there may be an increased risk of adverse effects
may raise the risk of nephrotoxicity
may raise the risk of nephrotoxicity
interaction with voclosporin may increase the risk of nephrotoxicity
interaction with voclosporin may increase the risk of nephrotoxicity
voclosporin may enhance the chances of nephrotoxicity
voclosporin may enhance the chances of nephrotoxicity
it increases the concentration of OATP1B1/1B3 substrates in serum
may enhance the serum concentration
the activity of the anthrax vaccine can be reduced when used in combination with voclosporin
increased serum concentration of methotrexate may lead to toxic effects
increased serum concentration of trimetrexate may lead to toxic effects
>10%:
Decreased GFR
Headache
Diarrhea
Cough
Anemia
1-10%:
Urinary tract infection
Dyspepsia
Upper abdominal pain
Abdominal pain
Alopecia
Renal Impairment
Fatigue
Decreased appetite
Mouth ulceration
Gingivitis
Tremor
Acute kidney injury
Hypertrichosis
Frequency undefined:
Pneumonia
Herpes Zoster
Increased blood creatinine
Gastroenteritis
Renal failure
Azotemia
QT prolongation
Cytomegalovirus infection
Oliguria
Hyperkalemia
Proteinuria
Voclosporin is contraindicated in patients hypersensitive to the active ingredient.
Pregnancy consideration:
The drug is not recommended during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of the drug in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: voclosporin
Pronounced: vok-loe-spo-rin
Why do we use voclosporin?
Voclosporin is a calcineurin inhibitor. It is used to treat lupus nephritis.